S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
My No. 1 dividend stock for a LIFETIME of income. (Ad)
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
Adam Mesh: “This Strategy Saved My Trading Career” (Ad)pixel
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
Here’s Your Own Billion-Dollar Trading Edge (Just $0.76 a Week) (Ad)pixel
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
My No. 1 dividend stock for a LIFETIME of income. (Ad)
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
Adam Mesh: “This Strategy Saved My Trading Career” (Ad)pixel
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
Here’s Your Own Billion-Dollar Trading Edge (Just $0.76 a Week) (Ad)pixel
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
My No. 1 dividend stock for a LIFETIME of income. (Ad)
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
Adam Mesh: “This Strategy Saved My Trading Career” (Ad)pixel
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
Here’s Your Own Billion-Dollar Trading Edge (Just $0.76 a Week) (Ad)pixel
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
My No. 1 dividend stock for a LIFETIME of income. (Ad)
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
Adam Mesh: “This Strategy Saved My Trading Career” (Ad)pixel
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
Here’s Your Own Billion-Dollar Trading Edge (Just $0.76 a Week) (Ad)pixel
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
NASDAQ:FOLD

Amicus Therapeutics - FOLD Stock Forecast, Price & News

$11.23
+0.02 (+0.18%)
(As of 03/29/2023 12:00 AM ET)
Add
Compare
Today's Range
$11.13
$11.30
50-Day Range
$11.05
$13.54
52-Week Range
$5.91
$13.84
Volume
2.12 million shs
Average Volume
2.22 million shs
Market Capitalization
$3.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.20

Amicus Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
35.4% Upside
$15.20 Price Target
Short Interest
Bearish
7.39% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.25
Upright™ Environmental Score
News Sentiment
0.65mentions of Amicus Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$4.63 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.38) to $0.19 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

637th out of 999 stocks

Pharmaceutical Preparations Industry

312th out of 489 stocks


FOLD stock logo

About Amicus Therapeutics (NASDAQ:FOLD) Stock

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.

Receive FOLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FOLD Stock News Headlines

My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
Q4 2022 Amicus Therapeutics Inc Earnings Call
Earnings Preview: Amicus Therapeutics
BTIG Reaffirms Their Buy Rating on Amicus (FOLD)
SVB Securities Reaffirms Their Buy Rating on Amicus (FOLD)
See More Headlines
Receive FOLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FOLD Company Calendar

Last Earnings
11/08/2021
Today
3/29/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:FOLD
CUSIP
03152W10
Employees
496
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$15.20
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+35.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
5 Analysts

Profitability

Net Income
$-236,570,000.00
Pretax Margin
-73.52%

Debt

Sales & Book Value

Annual Sales
$329.23 million
Book Value
$0.44 per share

Miscellaneous

Free Float
275,930,000
Market Cap
$3.17 billion
Optionable
Optionable
Beta
0.82

Social Links


Key Executives

  • Bradley Lewis CampbellBradley Lewis Campbell
    President, Chief Executive Officer & Director
  • Daphne E. Quimi
    Chief Financial Officer
  • Jill Weimer
    Chief Science Officer
  • Mitchell Goldman
    Chief Medical Officer
  • Patrik S. Florencio
    Senior VP, Global Chief Compliance & Risk Officer













FOLD Stock - Frequently Asked Questions

Should I buy or sell Amicus Therapeutics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FOLD shares.
View FOLD analyst ratings
or view top-rated stocks.

What is Amicus Therapeutics' stock price forecast for 2023?

5 analysts have issued 1-year target prices for Amicus Therapeutics' shares. Their FOLD share price forecasts range from $11.00 to $17.00. On average, they expect the company's share price to reach $15.20 in the next year. This suggests a possible upside of 35.4% from the stock's current price.
View analysts price targets for FOLD
or view top-rated stocks among Wall Street analysts.

How have FOLD shares performed in 2023?

Amicus Therapeutics' stock was trading at $12.21 on January 1st, 2023. Since then, FOLD shares have decreased by 8.0% and is now trading at $11.23.
View the best growth stocks for 2023 here
.

Are investors shorting Amicus Therapeutics?

Amicus Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 20,880,000 shares, an increase of 15.4% from the February 28th total of 18,090,000 shares. Based on an average daily volume of 2,120,000 shares, the short-interest ratio is presently 9.8 days.
View Amicus Therapeutics' Short Interest
.

When is Amicus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our FOLD earnings forecast
.

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) issued its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by $0.01. The biopharmaceutical company earned $79.55 million during the quarter, compared to analysts' expectations of $81.42 million. Amicus Therapeutics had a negative net margin of 71.83% and a negative trailing twelve-month return on equity of 141.73%. During the same quarter in the prior year, the company posted ($0.22) EPS.

What guidance has Amicus Therapeutics issued on next quarter's earnings?

Amicus Therapeutics issued an update on its FY 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $329.00 million-$329.00 million, compared to the consensus revenue estimate of $326.68 million.

What is John F. Crowley's approval rating as Amicus Therapeutics' CEO?

21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Morgan Stanley (6.35%), JPMorgan Chase & Co. (4.82%), Macquarie Group Ltd. (2.48%), Norges Bank (1.92%), Fiera Capital Corp (1.85%) and Geode Capital Management LLC (1.74%). Insiders that own company stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, David Michael Clark, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends
.

How do I buy shares of Amicus Therapeutics?

Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amicus Therapeutics' stock price today?

One share of FOLD stock can currently be purchased for approximately $11.23.

How much money does Amicus Therapeutics make?

Amicus Therapeutics (NASDAQ:FOLD) has a market capitalization of $3.17 billion and generates $329.23 million in revenue each year. The biopharmaceutical company earns $-236,570,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

How many employees does Amicus Therapeutics have?

The company employs 496 workers across the globe.

How can I contact Amicus Therapeutics?

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The official website for the company is www.amicusrx.com. The biopharmaceutical company can be reached via phone at (215) 921-7600, via email at afaughnan@amicusrx.com, or via fax at 609-662-2001.

This page (NASDAQ:FOLD) was last updated on 3/30/2023 by MarketBeat.com Staff